Scholarlink

Purpose <p>To evaluate whether prostate size influences perioperative, urinary, and sexual outcomes following Aquablation for benign prostatic hyperplasia (BPH), by comparing men with prostates &lt; 80&#xa0;cc and ≥ 80&#xa0;cc treated within a prospective real-world cohort.</p> Methods <p>This prospective, single-center cohort study included consecutive men undergoing Aquablation between 2023 and 2025. Patients were stratified by prostate volume (&lt; 80&#xa0;cc vs. ≥80&#xa0;cc). Baseline characteristics, perioperative parameters, and functional outcomes were assessed using validated instruments, including IPSS, IPSS-QoL, irritative subscore, ICIQ-SF, IIEF-EF, MSHQ-EjD, and MSHQ-bother, at baseline and at 3, 6, 12, and 24 months. Complications were graded according to the Clavien–Dindo classification.</p> Results <p>A total of 628 men were included (324 with prostates &lt; 80&#xa0;cc and 304 with prostates ≥ 80&#xa0;cc). Men with larger prostates had higher rates of preoperative catheter dependence (34% vs. 18.2%, <i>p</i> &lt; 0.001). Operative time (40.6 ± 14.1 vs. 36.2 ± 12.6&#xa0;min, <i>p</i> = 0.001) and hospitalization duration (2.5 ± 1.5 vs. 2.09 ± 0.8 days, <i>p</i> &lt; 0.001) were longer in the ≥ 80&#xa0;cc group. Both cohorts demonstrated marked and durable improvement in urinary symptoms, with mean IPSS improving from 24.5 to 6.7 in the &lt; 80&#xa0;cc group and from 24.9 to 6.0 in the ≥ 80&#xa0;cc group at 24 months. Irritative symptom scores improved from 10.3 to 3.5 and from 10.5 to 2.1, respectively (<i>p</i> &lt; 0.001). Sexual outcomes remained stable across prostate sizes, with preserved erectile function and low ejaculatory bother scores. High-grade complications (Clavien–Dindo III–IV) were uncommon and comparable between groups (2.7% vs. 4.3%), while reoperation rates remained low (3.1% vs. 3.9%).</p> Conclusion <p>Aquablation provides durable symptom relief with preservation of sexual function across a broad range of prostate volumes, supporting its role as a size-independent surgical treatment option for BPH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of prostate size on outcomes of aquablation: a prospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Dolev Perez,
  • Ariel Mamber,
  • Michael Pasherstnik,
  • Dmitry Koulikov,
  • Ala Eddin Natsheh,
  • Ofer Z. Shenfeld,
  • Ilan Z. Kafka,
  • Boris Chertin

摘要

Purpose

To evaluate whether prostate size influences perioperative, urinary, and sexual outcomes following Aquablation for benign prostatic hyperplasia (BPH), by comparing men with prostates < 80 cc and ≥ 80 cc treated within a prospective real-world cohort.

Methods

This prospective, single-center cohort study included consecutive men undergoing Aquablation between 2023 and 2025. Patients were stratified by prostate volume (< 80 cc vs. ≥80 cc). Baseline characteristics, perioperative parameters, and functional outcomes were assessed using validated instruments, including IPSS, IPSS-QoL, irritative subscore, ICIQ-SF, IIEF-EF, MSHQ-EjD, and MSHQ-bother, at baseline and at 3, 6, 12, and 24 months. Complications were graded according to the Clavien–Dindo classification.

Results

A total of 628 men were included (324 with prostates < 80 cc and 304 with prostates ≥ 80 cc). Men with larger prostates had higher rates of preoperative catheter dependence (34% vs. 18.2%, p < 0.001). Operative time (40.6 ± 14.1 vs. 36.2 ± 12.6 min, p = 0.001) and hospitalization duration (2.5 ± 1.5 vs. 2.09 ± 0.8 days, p < 0.001) were longer in the ≥ 80 cc group. Both cohorts demonstrated marked and durable improvement in urinary symptoms, with mean IPSS improving from 24.5 to 6.7 in the < 80 cc group and from 24.9 to 6.0 in the ≥ 80 cc group at 24 months. Irritative symptom scores improved from 10.3 to 3.5 and from 10.5 to 2.1, respectively (p < 0.001). Sexual outcomes remained stable across prostate sizes, with preserved erectile function and low ejaculatory bother scores. High-grade complications (Clavien–Dindo III–IV) were uncommon and comparable between groups (2.7% vs. 4.3%), while reoperation rates remained low (3.1% vs. 3.9%).

Conclusion

Aquablation provides durable symptom relief with preservation of sexual function across a broad range of prostate volumes, supporting its role as a size-independent surgical treatment option for BPH.